<DOC>
	<DOCNO>NCT03085706</DOCNO>
	<brief_summary>To assess safety peripheral blood mononuclear cell transplantation subarachnoid space treatment amyotrophic lateral sclerosis .</brief_summary>
	<brief_title>Transplantation Autologous Peripheral Blood Mononuclear Cells Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) rapidly evolve , fatal neurodegenerative disease result degeneration cortical , bulbar spinal motor neuron . The disease progress inexorably death , usually failure respiratory function , median duration 3 year . Recent clinical trial use various type stem cell , include mesenchymal stromal cell , neural stem cell , peripheral blood mononuclear cell ( PBMCs ) , represent promising strategy stem cell-based treatment ALS . It demonstrate inflammation neuronal death reduce ALS patient bone marrow transplantation . In addition , incidence immune response decrease autologous transplantation bone marrow cell ALS patient . PBMCs multi-potent stem cell attractive cell therapy approach ALS plasticity ability provide host tissue growth factor modulate host immune system . PBMCs use clinically adverse effect attribute administration . Early clinical investigation indicate transplantation autologous PBMCs dura feasible ALS patient ; however , one study limit three patient recruit eight patient . There still many question regard intrathecal transplantation PBMCs ALS . Therefore , retrospective study perform assess safety efficacy procedure test impact cell therapy approach ALS patient . Statistical analysis Data , express mean Â± SD , analyze use SPSS version 17.0 Windows ( SPSS Inc. , Chicago , IL , USA ) . Statistical analysis perform paired sample t-test . A value P &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>subject verifiable diagnosis ALS 0.5 2 year base diagnosis use Revised Criteria World Federation Neurology . The grades diagnosis clinically definite ALS clinically probable ALS ; ALS mildtomoderate base ALS Functional Rating ScaleRevised . Electrophysiological feature show compound muscle action potential ( CMAP ) amplitude motor nerve normal mild decline ; serum creatine kinase normal mild upper , less 500 U/L . use investigational agent within 30 day treatment ; severe cardiac , pulmonary , hepatic or/and hematic disease ; human immunodeficiency virus positivity sign symptoms consistent human immunodeficiency virus infection ; pregnant nursing woman ; history cancer le 5 year documentation diseasefree state ; history anaphylactic reaction hypersensitivity granulocyte colony stimulate factor ( GCSF ) ; alcohol drug abuse recent 1 year ; understand obey rule treatment ; blood donor recent 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>